DAX23.499 +0,6%ESt505.310 +0,4%Top 10 Crypto14,13 +5,4%Dow41.249 -0,3%Nas17.929 ±0,0%Bitcoin91.720 +0,2%Euro1,1251 ±0,0%Öl63,88 +1,2%Gold3.329 ±0,0%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 NVIDIA 918422 Tesla A1CX3T Allianz 840400 Lufthansa 823212 Commerzbank CBK100 Mercedes-Benz Group (ex Daimler) 710000 Deutsche Bank 514000 RENK RENK73 Siemens Energy ENER6Y BASF BASF11 Infineon 623100 Palantir A2QA4J Volkswagen (VW) vz. 766403 Amazon 906866
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Zoll-Hoffnung: DAX geht nach Rekord höher ins Wochenende -- US-Börsen letztlich uneins -- Commerzbank verdient mehr -- Coinbase, BVB, Siemens Energy, SoundHound, Palantir, Strategy, Pinterest im Fokus
Top News
NVIDIA-Aktie vor dem Ausbruch? Darum könnte die anstehende Bilanz neuen Schub verleihen NVIDIA-Aktie vor dem Ausbruch? Darum könnte die anstehende Bilanz neuen Schub verleihen
So entwickeln sich Bitcoin, Litecoin & Co am Samstagnachmittag am Kryptomarkt So entwickeln sich Bitcoin, Litecoin & Co am Samstagnachmittag am Kryptomarkt
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Theravance Biopharma Aktie

NeuKaufenVerkaufen
Aktien-Sparplan anlegen
8,70 EUR -0,10 EUR -1,14 %
FSE
8,99 USD -0,91 USD -9,15 %
nachbörslich
BTT
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.399,09 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA1137V

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINKYG8807B1068

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolTBPH

Theravance Biopharma Aktien News

DatumMeistgelesen
PR NewswireViatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI® (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
PR NewswireTheravance Biopharma, Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update
PR NewswireTheravance Biopharma to Report Third Quarter 2023 Financial Results on November 7, 2023
PR NewswireTheravance Biopharma to Participate in an Upcoming Investor Conference
PR NewswireTheravance Biopharma to Present New Ampreloxetine Data at the 2023 International Congress of Parkinson's Disease and Movement Disorders
PR NewswireTheravance Biopharma, Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update
PR NewswireTheravance Biopharma to Report Second Quarter 2023 Financial Results on August 7, 2023
PR NewswireTheravance Biopharma, Inc. Announces Orphan Drug Designation Granted to Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Patients with Multiple System Atrophy
PR NewswireTheravance Biopharma, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update
PR NewswireTheravance Biopharma to Report First Quarter 2023 Financial Results on May 8, 2023
PR NewswireTheravance Biopharma, Inc. Announces Appointment of Jim Kelly, Managing Director at Weiss Asset Management, to Board of Directors
PR NewswireTheravance Biopharma to Participate in an Upcoming Investor Conference
PR NewswireTheravance Biopharma to Participate in an Upcoming Investor Conference
PR NewswireTheravance Biopharma, Inc. Announces Strategic Actions and Reports Fourth Quarter / Full Year 2022 Financial Results and Business Update
PR NewswireTheravance Biopharma to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023
PR NewswireTheravance Biopharma to Participate in an Upcoming Investor Conference
PR NewswireTheravance Biopharma, Inc. Highlights 2022 Accomplishments and 2023 Key Targets
PR NewswireTheravance Biopharma, Inc. Announces Preliminary Results of Tender Offer
PR NewswireTheravance Biopharma, Inc. Reports Third Quarter 2022 Financial Results, Provides Business Update and Extends Tender Offer
PR NewswireAmpreloxetine Data in Neurogenic Orthostatic Hypotension to be Presented at the 33rd International Symposium on the Autonomic Nervous System
PR NewswireTheravance Biopharma to Report Third Quarter 2022 Financial Results on November 7, 2022
PR NewswireTheravance Biopharma to Present New Ampreloxetine Data in Neurogenic Orthostatic Hypotension at the 33rd International Symposium on the Autonomic Nervous System
PR NewswireTheravance Biopharma Announces Tender Offer For Up To $95 Million Of Its Ordinary Shares
PR NewswireTheravance Biopharma Announces Tender Offer For Up To $95 Million Of Its Ordinary Shares
PR NewswireTheravance Biopharma, Inc. Initiates $250 Million Capital Return Program
PR NewswireTheravance Biopharma, Inc. Initiates $250 Million Capital Return Program
PR NewswireTheravance Biopharma to Present at Upcoming Investor Conferences
PR NewswireTheravance Biopharma, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update
PR NewswireTheravance Biopharma to Report Second Quarter 2022 Financial Results on August 4, 2022
PR NewswireTheravance Biopharma Announces Tender Offer For Outstanding 3.25% Convertible Senior Notes Due 2023
PR NewswireTheravance Biopharma to Sell TRELEGY ELLIPTA Royalty Interests to Royalty Pharma for Approximately $1.1 Billion in Upfront Cash with Over $1.5 Billion in Potential Total Value
PR NewswireTheravance Biopharma to Sell TRELEGY ELLIPTA Royalty Interests to Royalty Pharma for Approximately $1.1 Billion in Upfront Cash with Over $1.5 Billion in Potential Total Value
Wer­bung

Theravance Biopharma News

Theravance Biopharma News: auf dieser Seite finden Sie alle Theravance Biopharma News und Nachrichten zur Theravance Biopharma Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Theravance Biopharma News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Theravance Biopharma News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.